VCLIP Post-Market Study, Long-term Follow-up on LAA Exclusion Using AtriClip
Completed · Not applicable · NCT05101993
Conditions: Left Atrial Appendage Absent
At a glance
- Research payments reported, 2025
- $435
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 156
About the trial
- Sponsor
- AtriCure, Inc.
- Tested
- AtriClip (device)
- Dates
- Started 2022-01-27; completion 2024-07-22
- Results posted
- Yes
Retrospective-prospective, multi-center, non-randomized, unblinded, post-market study to evaluate the long-term performance and safety of AtriClip® FLEX-V LAA and PRO•V LAA Exclusion devices for exclusion of the left atrial appendage of the heart during concomitant cardiac procedures.
From ClinicalTrials.gov, last updated 2025-07-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Atricure, Inc. reported $435 in research payments for this study in 2025 (1 payments).
Products named: Atriclip Laa Exclusion System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- St Vincent Health Inc DBA Ascension St Vincent $435
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.